课题基金 / 基金详情

SNRI, bupropion and mirtazapine use during pregnancy and the risk of persistent pulmonary hypertension of the newborn (PPHN)

SNRI, bupropion and mirtazapine use during pregnancy and the risk of persistent pulmonary hypertension of the newborn (PPHN)
妊娠期间使用 SNRI、安非他酮和米氮平以及新生儿持续性肺动脉高压 (PPHN) 的风险
批准号：
296155
负责人：
Brard Anick
金额：
$7.29万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Miscellaneous Programs
财政年份：
2013
资助国家：
加拿大
项目状态：
已结题
起止时间：
2013-10-01 至 2014-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=296155&lang=en
关键词：
Antidepressants Bupropion Cardiac Malformations Mirtazapine Persistent Pulmonary Hypertension Of The Newborn. Pregnancy Snri

项目摘要

项目成果

Brard Anick的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Studies from the US and Scandinavia have shown that SSRI use during pregnancy, specifically after the 20th week of gestation, was associated with an increased risk of PPHN, a severe condition leading to disability and mortality. As of now however, limited
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The CAnadian Mother-Child Initiative - knowledge mobilization from COnception to adulthood - CAMCCO-Outreach.
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform - SPOR Supplement
Canada Research Chair - Tier 1
  • 批准号：
    454003
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2021
  • 负责人：
    Brard Anick
  • 依托单位：
    Universit de Montral
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform
海外基金